GSK/Theravance Press On With LABA After Cmtes. Cut Asthma Indication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Many pharmaceutical firms' corporate plans for developing new asthma products that combine long-acting beta agonists with inhaled corticosteroids are not seriously affected by the recommendation of three FDA advisory committees to eliminate the asthma indication for single-entity LABA products
You may also be interested in...
New Foradil Inhaler Falls Prey To Concerns About Single-Entity LABA Products
Novartis Foradil Certihaler (formoterol fumarate inhalation powder) is the first victim of a recommendation by several FDA advisory committees to withdraw the asthma indication for formoterol and salmeterol
FDA Panels Favor Advair, Symbicort Over Single-Entity LABA Products For Asthma
Agency must consider whether to change labeling, institute REMS or withdraw the indications for Serevent and Foradil, OND's Jenkins says.
Schering/Novartis To Develop Once-Daily Inhalation Combination For Asthma, COPD
Fixed-dose therapy will combine Novartis' investigational beta2-agonist indacaterol with Schering-Plough's Asmanex.